Innovate Biopharmaceuticals Inc., of Raleigh, N.C., said it entered securities purchase agreements with certain institutional investors providing for the purchase and sale of about 4.3 million shares of common stock at a purchase price of $2.025 per share, in a registered direct offering priced at-the-market for aggregate gross proceeds of about $8.7 million.